source
- Ultragenyx to cut 20% of staff and halve R&D budget as it pivots to commercial salesUltragenyx announced it will reduce its workforce by about 20%, bringing headcount down to roughly 1,000 employees. The cuts follow an earlier 10% reduction announced in February and are part of a…
- Sanofi halts development of Nurix-partnered STAT6 degrader, triggering sharp drop in Nurix stockSanofi announced it is ending work on SAR448272, an experimental oral drug that was intended to degrade the STAT6 protein, which is linked to inflammatory diseases. The biotech firm Nurix, which l…